
A growing obesity epidemic may affect the outcome of treatment for those dealing with cancer, according to a new study of adults and teens being treated for acute lymphoblastic leukemia (ALL). Researchers called for further study of how weight affects the response to different chemotherapy regimens for ALL. “We have known for roughly 15 years that obesity affects survival in pediatric patients treated for ALL, and more recently, we are recognizing a similar relationship in adult populations,” said lead author Dr. Shai Shimony, an advanced fellow at the Dana-Farber Cancer Institute in Boston. “But we wanted more granular data on this, to understand why this correlation exists, and how dependent it is on age.” For the study, Shimony’s team collected data on 388 individuals (average age, 24 years) who were treated on Dana-Farber Consortium pediatric regimens for ALL from 2008 to 2021. The investigators examined the relationship between body mass index (BMI, a measure of body fat based on height and weight); age; toxicities; and treatment outcomes. In all, nearly 47% of the individuals were overweight or obese. The study found they had a higher rate of non-relapse death, nearly 12%, compared to just under 3% for those with a normal BMI. They also had a lower event-free survival rate — 63% versus 77% at four years. (Event-free survival is the length of time after… read on > read on >